President Donald Trump has issued an executive order directing federal agencies to accelerate their evaluation of psychedelic drugs as potential treatments for mental health disorders.
The directive, signed in the Oval Office on Saturday, specifically focuses on expediting reviews of psilocybin and ibogaine for therapeutic purposes. These substances have shown promise in treating various mental health conditions in recent research studies.
During the signing ceremony, Trump made a lighthearted comment about the substances, asking “Can I have some, please?” while endorsing the potential benefits of both psilocybin and ibogaine.
The executive order represents a significant shift in federal policy toward psychedelic research, potentially opening new avenues for mental health treatment options that have traditionally faced regulatory barriers.
This development could impact how quickly these alternative therapies become available to patients struggling with mental health disorders across the country.
